chloroquine has been researched along with Myasthenia Gravis in 15 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine induced a myasthenic syndrome in a patient taking the drug for presumable reticular erythematous mucinosis." | 8.77 | Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. ( Bednarik, J; Bourgeois, P; Carton, H; Robberecht, W; van Hees, J, 1989) |
| "The anti-rheumatoid drug D-penicillamine (D-pen) has a reactive sulfhydryl group capable of modifying self antigens, and can provoke typical autoantibody-mediated myasthenia gravis (MG), especially in DR1+ individuals." | 7.70 | T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. ( Hill, M; Moss, P; Newsom-Davis, J; Willcox, N; Wordsworth, P, 1999) |
| "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis." | 7.67 | Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis. ( Hearn, J; Tiliakos, NA, 1986) |
| "Chloroquine induced a myasthenic syndrome in a patient taking the drug for presumable reticular erythematous mucinosis." | 4.77 | Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. ( Bednarik, J; Bourgeois, P; Carton, H; Robberecht, W; van Hees, J, 1989) |
| "The anti-rheumatoid drug D-penicillamine (D-pen) has a reactive sulfhydryl group capable of modifying self antigens, and can provoke typical autoantibody-mediated myasthenia gravis (MG), especially in DR1+ individuals." | 3.70 | T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. ( Hill, M; Moss, P; Newsom-Davis, J; Willcox, N; Wordsworth, P, 1999) |
| "A middle-age woman had intermittently had chloroquine as an antimalarial agent for 21 years." | 3.68 | Persisting chloroquine-induced myasthenia? ( De Bleecker, J; De Reuck, J; Meire, F; Quatacker, J, 1991) |
| "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis." | 3.67 | Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis. ( Hearn, J; Tiliakos, NA, 1986) |
| "Myasthenic reaction with partial neuromuscular block in the electromyogram and increased antibodies against acetylcholine-receptor protein developed during chloroquine administration over two months in a 52-year-old man known for eight years ot have rheumatoid arthritis." | 3.66 | [Myasthenia syndrome during chloroquine treatment (author's transl)]. ( Fateh-Moghadam, A; Schumm, F; Wiethölter, H, 1981) |
| "A young woman on chronic corticosteroid treatment for systemic lupus erythematosus developed a myasthenia-like syndrome 7 weeks after starting chloroquine therapy." | 1.27 | Chloroquine myopathy and myasthenia-like syndrome. ( Cornelio, F; Mantegazza, R; Mora, M; Pareyson, D; Sghirlanzoni, A, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (66.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Guidon, AC | 1 |
| Amato, AA | 1 |
| Killen, JA | 1 |
| Lindstrom, JM | 1 |
| Pichon, P | 1 |
| Soichot, P | 1 |
| Loche, D | 1 |
| Chapelon, M | 1 |
| Schumm, F | 1 |
| Wiethölter, H | 1 |
| Fateh-Moghadam, A | 1 |
| Savage, CO | 1 |
| Brooks, CJ | 1 |
| Harcourt, GC | 1 |
| Picard, JK | 1 |
| King, W | 1 |
| Sansom, DM | 1 |
| Willcox, N | 2 |
| Brüggemann, W | 1 |
| Herath, H | 1 |
| Ferbert, A | 1 |
| Hill, M | 1 |
| Moss, P | 1 |
| Wordsworth, P | 1 |
| Newsom-Davis, J | 1 |
| Argov, Z | 1 |
| Mastaglia, FL | 1 |
| De Bleecker, J | 1 |
| De Reuck, J | 1 |
| Quatacker, J | 1 |
| Meire, F | 1 |
| Robberecht, W | 1 |
| Bednarik, J | 1 |
| Bourgeois, P | 1 |
| van Hees, J | 1 |
| Carton, H | 1 |
| Muirden, KD | 1 |
| Sghirlanzoni, A | 1 |
| Mantegazza, R | 1 |
| Mora, M | 1 |
| Pareyson, D | 1 |
| Cornelio, F | 1 |
| Hearn, J | 1 |
| Tiliakos, NA | 1 |
| Thomas, PK | 1 |
| Oosterhuis, HJ | 1 |
| de Haas, WH | 1 |
4 reviews available for chloroquine and Myasthenia Gravis
| Article | Year |
|---|---|
COVID-19 and neuromuscular disorders.
Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Heal | 2020 |
Drug therapy: Disorders of neuromuscular transmission caused by drugs.
Topics: Aged; Animals; Anti-Bacterial Agents; Anticonvulsants; Cardiovascular Agents; Chloroquine; Drug-Rela | 1979 |
Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction.
Topics: Adult; Chloroquine; Electric Stimulation; Electromyography; Erythema; Female; Humans; Injections; Ma | 1989 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
1 trial available for chloroquine and Myasthenia Gravis
| Article | Year |
|---|---|
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
11 other studies available for chloroquine and Myasthenia Gravis
| Article | Year |
|---|---|
Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
Topics: Adjuvants, Immunologic; Animals; Autoimmune Diseases; B-Lymphocytes; Chloroquine; Cytotoxins; Lympho | 1984 |
[Myasthenic syndrome induced by chloroquine poisoning: an unusual clinical form confirmed by ocular involvement].
Topics: Adult; Chloroquine; Electromyography; Eye Diseases; Humans; Male; Myasthenia Gravis | 1984 |
[Myasthenia syndrome during chloroquine treatment (author's transl)].
Topics: Arthritis, Rheumatoid; Chloroquine; Electromyography; Humans; Male; Middle Aged; Myasthenia Gravis | 1981 |
Human vascular endothelial cells process and present autoantigen to human T cell lines.
Topics: Antigen Presentation; Antigens, CD; Autoantigens; B7-1 Antigen; CD28 Antigens; CD58 Antigens; Cell A | 1995 |
[Follow-up and immunologic findings in drug-induced myasthenia].
Topics: Aged; Antirheumatic Agents; Autoantibodies; Chloroquine; Female; Follow-Up Studies; HLA-DR4 Antigen; | 1996 |
T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes.
Topics: Aged; Amino Acid Sequence; Antirheumatic Agents; Autoimmune Diseases; Base Sequence; Blood Proteins; | 1999 |
Persisting chloroquine-induced myasthenia?
Topics: Chloroquine; Edrophonium; Female; Humans; Malaria; Middle Aged; Muscles; Myasthenia Gravis | 1991 |
Chloroquine myopathy and myasthenia-like syndrome.
Topics: Adult; Biopsy; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Microscopy, Electron; Mus | 1988 |
Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Humans; Male; Myastheni | 1986 |
Myopathy.
Topics: Alcoholism; Chloroquine; Glucosyltransferases; Glycogen Storage Disease; Humans; Ischemia; Muscular | 1970 |
Curare sensitivity and myastheniform symptoms in patients with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blepharoptosis; Chloroquine; Diplopia; Eye Manifestations; Female; Huma | 1969 |